Ruggiero H A, Castellanos H, Caprissi L F, de Caprissi E S, Ruggiero L H
Clin Cardiol. 1983 May;6(5):212-6. doi: 10.1002/clc.4960060504.
The effects of heparin were studied in a group of 42 patients with preinfarction angina (PA) and acute myocardial infarction (AMI) whose plasma fibrinogen was increased. Plasma fibrinogen was measured by the turbidimetric method in timol turbidimetric units. Statistically significant results proved that heparin reduces the plasma fibrinogen progressively over a treatment period of 6 weeks. During the first three weeks a dose of 1 cc (50 mg or 5000 IU) was given by intravenous injection at 6-h intervals, this was followed by a dose of 2 cc (100 mg or 10,000 IU) given by subcutaneous injection at 12-h intervals for a further three weeks. Hyperfibrinogenemia is perhaps one of the most important factors in the thrombophilic syndrome, and at the same time it is one of the fundamental physiopathological alterations observed in AMI and PA. Because heparin reduces hyperfibrinogenemia it has a beneficial effect in these diseases.
在一组42例血浆纤维蛋白原升高的梗死前心绞痛（PA）和急性心肌梗死（AMI）患者中研究了肝素的作用。采用比浊法以麝香草酚比浊单位测定血浆纤维蛋白原。具有统计学意义的结果证明，在6周的治疗期内，肝素可使血浆纤维蛋白原逐渐降低。在前三周，每6小时静脉注射1毫升（50毫克或5000国际单位），随后三周，每12小时皮下注射2毫升（100毫克或10000国际单位）。高纤维蛋白原血症可能是血栓形成倾向综合征中最重要的因素之一，同时也是在AMI和PA中观察到的基本生理病理改变之一。由于肝素可降低高纤维蛋白原血症，因此它对这些疾病具有有益作用。
